Amylin acquisition marks new chapter in Bristol-Myers Squibb, AstraZeneca diabetes alliance

Bristol-Myers Squibb’s (NYSE:BMY) $7 billion acquisition of Amylin Phramaceuticals (NASDAQGS:AMLN) is one of the largest diabetes deals for the year to date. Given Bristol-Myers Squibb’s a…
Read the full story: MedCity News